Skip to main content
SpringerLink
Log in

In Vitro Drug Resistance Profiles in Childhood Acute Lymphoblastic Leukemia

  • Conference paper
Acute Leukemias V

Part of the book series: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 37))

  • 72 Accesses

Abstract

In 1987, the short-term MTT assay was adapted in our laboratory to study in vitro cellular drug resistance in childhood acute lymphoblastic leukemia (ALL). In this paper, some clinically relevant data obtained with this method are summarized:

  1. 1.

    In a small retrospective study we showed that in vitro drug resistance was related to the long-term clinical outcome. In 1989 a nationwide, prospective study including 128 patients was started to confirm these data. Patients with cells relatively in vitro resistant to prednisolone had a significantly lower 2-year probability of disease-free survival (pDFS 0.67) than sensitive cases (pDFS 0.98). In vitro resistance to L-asparaginase and daunorubicin were also significantly related to outcome; for vincristine the relation was borderline significant. Combining the results for prednisolone, L-asparaginase and vincristine, the pDFS was 100% for the sensitive, 83% for the intermediately sensitive and 60% for the in vitro resistant patients (p >.001). In vitro drug resistance was an independent prognostic factor at multivariate analysis.

  2. 2.

    In vitro resistance of a group of 99 children with relapsed ALL was compared to that of 137 children with untreated ALL. Cells from children with relapsed ALL were significantly more in vitro resistant to corticosteroids, anthracyclines, antimetabolites and L-asparaginase but not to vinca-alkaloids, epipodophyllotoxins and ifosfamide. Resistance profiles and the degree of resistance highly differed between individual patients.

  3. 3.

    The prognostic significance of several cell biological features can mainly be explained by drug resistance. DNA hyperdiploid cases have a better prognosis than non-hyperdiploid cases. Hyperdiploid cALL cases were significantly more in vitro sensitive to the antimetabolites 6TG, 6-MP and araC but not to other drugs. Immunophenotypic subgroups of ALL had their own specific drug resistance profiles that might explain the differences in prognosis related to phenotype.

Conclusions. Drug resistance measured with the MTT assay is an important predictor of clinical outcome in ALL and should be used for risk-group stratification in BFM-oriented treatment. Biological risk groups have their own specific in vitro drug resistance profiles that might be helpful in rational design of risk-group adapted therapies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Veerman AJP, Pieters R. Drug sensitivity assays in leukemia and lymphoma. Br J Haematol 1990; 74: 381.

    Article  PubMed  CAS  Google Scholar 

  2. Pieters R, Loonen AH, Huismans DR, Broekema GJ, Dirven MWJ, Heyenbrok MW, Hählen K, Veerman AJP. In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 1990; 76: 2327.

    PubMed  CAS  Google Scholar 

  3. Pieters R, Huismans DR, Loonen AH, Hählen K, van der Does-van den Berg A, van Wering ER, Veerman AJP. Relation of cellular drug resistance to long-term clinical outcome in childhood acute lymphoblastic leukemia. Lancet 1991; 338: 399.

    Article  PubMed  CAS  Google Scholar 

  4. Pui CH, Crist WM, Look AT. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood 1990; 76: 1449.

    PubMed  CAS  Google Scholar 

  5. Whitehead VM, Vuhich M-J, Lauer SJ, Mahoney D, Carroll AJ, Shuster Esseltine DW, Payment C, Look AT, Akabutu J, Bowen T, Taylor LD, Camitta B, Pullen DJ. Accumulation of high levels of methotrexate polyglutamates in lymphoblasts from children with hyperdiploid (>5o chromosomes) B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group Study. Blood 1992; 80: 1316.

    PubMed  CAS  Google Scholar 

  6. Pinkel D. Curing children of leukemia. Cancer 1987; 10: 1683.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, Free University Hospital, 1007 MB, Amsterdam, The Netherlands

    R. Pieters, G. J. L. Kaspers, E. Klumper & A. J. P. Veerman

  2. Dutch Childhood Leukemia Study Group, The Hague, The Netherlands

    E. R. van Wering, A. van der Does-van den Berg & A. J. P. Veerman

Authors
  1. R. Pieters
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. J. L. Kaspers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Klumper
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. R. van Wering
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. van der Does-van den Berg
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A. J. P. Veerman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, University of Göttingen, Robert-Koch-Strasse 40, 37075, Göttingen, Germany

    W. Hiddemann  & W. Plunkett  & 

  2. Department of Internal Medicine, University of Münster, Albert-Schweitzer-Strasse 33, 48145, Münster, Germany

    T. Büchner

  3. Department of Pediatric Oncology, University of Münster, Albert-Schweitzer-Strasse 33, 48145, Münster, Germany

    J. Ritter

  4. Department of Internal Medicine, MD Anderson Cancer Center, 1515 Holcombe Blvd., 77030, Houston, TX, USA

    B. Wörmann M.D., Ph.D.  & M. J. Keating M.D., B.S.  & 

  5. Koordinierungsstelle, Deutsche Krebsgesellschaft e.V., Thea-Bähnisch-Weg 12, 30657, Hannover, Germany

    U. Creutzig

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Pieters, R., Kaspers, G.J.L., Klumper, E., van Wering, E.R., van der Does-van den Berg, A., Veerman, A.J.P. (1996). In Vitro Drug Resistance Profiles in Childhood Acute Lymphoblastic Leukemia. In: Hiddemann, W., et al. Acute Leukemias V. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 37. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78907-6_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-78907-6_19

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-78909-0

  • Online ISBN: 978-3-642-78907-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation